NEWGENERISProject reference: 16320
Funded under: FP6-FOOD
Development and application of biomarkers of dietary exposure to genotoxic and immunotoxic chemicals and of biomarkers of early effects, using mother-child birth cohorts and biobanks
Total cost:EUR 15 661 101
EU contribution:EUR 13 594 976
Topic(s):FOOD-2004-T18.104.22.168 - Developing biomarkers of exposure to chemicals and biomarkers of effects, using mother-child birth cohorts and biobanks
Call for proposal:FP6-2004-FOOD-3-A
Funding scheme:IP - Integrated Project
NewGeneris will test the hypothesis that maternal exposure to dietary compounds with carcinogenic and iimunotoxic properties results in in utero exposure and molecular events in the unborn child leading to increased risk of cancer and imnune disorders in later childhood. B??rmarkers of exposure, carcinogenic and iimunotoxic risks and of susceptibility will be developed and applied using higfr throughput techniques. Existing European mother-child birth cohorts will be used while new biobanks will be set up in different European regions to generate specific information, and to collect uitoilical cord blood sanples. Training and educational activities will be carried out. New3eneris will address the following objectives:
(1) Dietary exposure of pregnant wonnen to dietary carcinogens and iirmunotoxins will be assessed using available questionnaires fron existing mother/child birth cohorts.
(2)Epidemiological surveys of mother/child birth cohorts will be used to study associations between maternal dietary exposure, and childhood cancer risk factors and imnune disorders
(3) Paternal exposure to dietary toxins will be considered as an additional genetic risk.
(4) An in vitro model of transplacental perfusion will be used to better understand in utero exposure to selected toxins.
(5) In cord blood sanples from existing cohorts and newly initiated biobanks bianarkers will be used to assess fetal exposure to these compounds and compared with maternal exposure.
(6) In the sane sanples, genetic pathways indicative of risks of cancer and immune disorders in later childhood will be studied by analysis of lynphocytic gene expression and protecmics profiles.
(7) Liter-individual variability in responses will be evaluated by gene-typing of infants' ENA, and by phenotyping for ENA-repair activities.
(8) Overall public health implications as well as ethical issues, will be addressed.
(9) Results will be disseminated to EU food industry.
10 19 49 HEIDELBERG
1072 Blindern OSLO
4404, Nydalen OSLO
CERDANYOLA DEL VALLES (BARCELONA)